RAPT Therapeutics (RAPT) Enterprise Value (2020 - 2024)
Historic Enterprise Value for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to -$97.9 million.
- Therapeutics' Enterprise Value rose 4701.45% to -$97.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$97.9 million, marking a year-over-year increase of 4701.45%. This contributed to the annual value of -$158.9 million for FY2023, which is 3621.74% up from last year.
- As of Q3 2024, Therapeutics' Enterprise Value stood at -$97.9 million, which was up 4701.45% from -$114.8 million recorded in Q2 2024.
- Therapeutics' Enterprise Value's 5-year high stood at -$97.9 million during Q3 2024, with a 5-year trough of -$249.1 million in Q4 2022.
- Moreover, its 5-year median value for Enterprise Value was -$173.0 million (2022), whereas its average is -$167.7 million.
- As far as peak fluctuations go, Therapeutics' Enterprise Value plummeted by 7581.04% in 2022, and later skyrocketed by 4701.45% in 2024.
- Therapeutics' Enterprise Value (Quarter) stood at -$111.5 million in 2020, then tumbled by 70.08% to -$189.7 million in 2021, then plummeted by 31.33% to -$249.1 million in 2022, then skyrocketed by 36.22% to -$158.9 million in 2023, then soared by 38.37% to -$97.9 million in 2024.
- Its Enterprise Value stands at -$97.9 million for Q3 2024, versus -$114.8 million for Q2 2024 and -$141.6 million for Q1 2024.